Real-time Estimate
Cboe BZX
02:37:35 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
1.615
USD
|
-2.71%
|
|
-8.89%
|
-18.41%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
150
|
1,081
|
255.9
|
284.9
|
235.4
|
-
|
-
|
Enterprise Value (EV)
1 |
150
|
1,081
|
255.9
|
284.9
|
235.4
|
235.4
|
235.4
|
P/E ratio
|
-1.86
x
|
-6.61
x
|
-1.93
x
|
-2.96
x
|
-2.23
x
|
-2
x
|
-2.26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
263
x
|
57.6
x
|
18.9
x
|
7.93
x
|
EV / Revenue
|
-
|
-
|
-
|
263
x
|
57.6
x
|
18.9
x
|
7.93
x
|
EV / EBITDA
|
-
|
-16.9
x
|
-2.54
x
|
-3.02
x
|
-2.65
x
|
-2.25
x
|
-2.23
x
|
EV / FCF
|
-
|
-14.9
x
|
-2.53
x
|
-2.89
x
|
-2.62
x
|
-2.51
x
|
-2.65
x
|
FCF Yield
|
-
|
-6.71%
|
-39.6%
|
-34.6%
|
-38.1%
|
-39.8%
|
-37.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,780
|
137,416
|
139,819
|
141,728
|
141,816
|
-
|
-
|
Reference price
2 |
10.15
|
7.870
|
1.830
|
2.010
|
1.660
|
1.660
|
1.660
|
Announcement Date
|
4/7/21
|
2/28/22
|
3/6/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
1.082
|
4.086
|
12.47
|
29.68
|
EBITDA
1 |
-
|
-64.03
|
-100.6
|
-94.26
|
-88.8
|
-104.6
|
-105.7
|
EBIT
1 |
-
|
-96.91
|
-123.8
|
-111.2
|
-104
|
-110.4
|
-107.2
|
Operating Margin
|
-
|
-
|
-
|
-10,274.58%
|
-2,545.99%
|
-885.56%
|
-361.32%
|
Earnings before Tax (EBT)
1 |
-
|
-94.99
|
-132.4
|
-95.96
|
-100.1
|
-110.4
|
-107.2
|
Net income
1 |
-36.61
|
-94.99
|
-132.4
|
-95.96
|
-100.1
|
-110.4
|
-107.2
|
Net margin
|
-
|
-
|
-
|
-8,868.76%
|
-2,450.73%
|
-885.56%
|
-361.32%
|
EPS
2 |
-5.450
|
-1.190
|
-0.9500
|
-0.6800
|
-0.7450
|
-0.8300
|
-0.7350
|
Free Cash Flow
1 |
-
|
-72.58
|
-101.3
|
-98.55
|
-89.8
|
-93.8
|
-89
|
FCF margin
|
-
|
-
|
-
|
-9,107.76%
|
-2,197.48%
|
-752.27%
|
-299.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/7/21
|
2/28/22
|
3/6/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.254
|
0.205
|
0.223
|
0.4
|
0.457
|
0.6795
|
1.17
|
1.758
|
2.3
|
2.9
|
EBITDA
1 |
-20.38
|
-27.4
|
-25.82
|
-22.89
|
-24.46
|
-23.7
|
-22.87
|
-22.61
|
-25.08
|
-20.55
|
-21.6
|
-22.7
|
-23.9
|
-24.5
|
-25.6
|
EBIT
1 |
-27.79
|
-27.14
|
-30.2
|
-27.66
|
-38.84
|
-29.22
|
-26.89
|
-27.18
|
-27.88
|
-23.36
|
-25.02
|
-27.02
|
-28.62
|
-28.3
|
-29.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-11,504.33%
|
-13,118.05%
|
-12,186.1%
|
-6,970.75%
|
-5,111.6%
|
-3,681.6%
|
-2,309.74%
|
-1,628.1%
|
-1,230.43%
|
-1,013.79%
|
Earnings before Tax (EBT)
1 |
-29.42
|
-35.18
|
-32.41
|
-31.71
|
-33.14
|
-23.61
|
-25.57
|
-24.73
|
-22.05
|
-19.47
|
-25.02
|
-27.02
|
-28.62
|
-28.3
|
-29.4
|
Net income
1 |
-29.42
|
-35.18
|
-32.41
|
-31.71
|
-33.14
|
-23.61
|
-25.57
|
-24.73
|
-22.05
|
-19.47
|
-25.02
|
-27.02
|
-28.62
|
-28.3
|
-29.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-9,295.67%
|
-12,474.63%
|
-11,088.79%
|
-5,512%
|
-4,261.27%
|
-3,681.6%
|
-2,309.74%
|
-1,628.1%
|
-1,230.43%
|
-1,013.79%
|
EPS
2 |
-0.2100
|
-0.2500
|
-0.2300
|
-0.2300
|
-0.2400
|
-0.1700
|
-0.1800
|
-0.1700
|
-0.1600
|
-0.1400
|
-0.1900
|
-0.2050
|
-0.2200
|
-0.2100
|
-0.2050
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/7/22
|
3/6/23
|
5/11/23
|
8/7/23
|
11/9/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-72.6
|
-101
|
-98.5
|
-89.8
|
-93.8
|
-89
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
5.76
|
10.7
|
4.51
|
6.8
|
11.5
|
15
|
Capex / Sales
|
-
|
-
|
-
|
416.82%
|
166.4%
|
92.23%
|
50.54%
|
Announcement Date
|
4/7/21
|
2/28/22
|
3/6/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
1.66
USD Average target price
2.75
USD Spread / Average Target +65.66% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.41% | 235M | | +69.57% | 62.86B | | -0.75% | 41.38B | | +45.66% | 40.38B | | -10.72% | 27.64B | | +14.26% | 26.46B | | -22.17% | 18.9B | | +4.85% | 12.67B | | +23.91% | 12.27B | | +28.25% | 12.07B |
Other Biotechnology & Medical Research
|